Consultation closes: Oral semaglutide product-specific BE guidance
EMAConsultation deadline
Low impact in 78 days
Generic developers can comment on the bioequivalence approach for semaglutide tablets.
Add to Google Calendar Subscribe to all dates (iCal)
Get the outcome, not just the date
When EMA publishes the final text, VigiEye subscribers get an AI summary of what changed versus the draft and who it affects.
Free weekly "EU regulatory week ahead" email. Or start monitoring.
Related upcoming dates
Dates are taken from the official source above. Agencies occasionally reschedule; confirm on the source before acting.